** charts before earnings **
** charts after earnings **
Reported Q4 results. Total net revs fell 5% from the prior quarter to CAD$72.1 mln; consumer cannabis net revs decreased 9% over the previous quarter, impacted by a 30% decrease in the average net selling price per gram of consumer cannabis. Medical cannabis net revs increased +4% from the prior quarter. Adj. EBITDA was a loss of CAD$(34.6) mln. Co noted that is has "slipped from its top position in Canadian consumer"; co plans to execute certain tactical initiatives in the category to return to its leadership position. Moves to its lowest levels since May.
No comments:
Post a Comment